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1. Introduction 
The cancer stem cell model for tumor progression is the first model of its type to suggest 
that only one subpopulation of cancer cells is capable of proliferating indefinitely. These 
cells resemble normal stem cells in their capacity for self-renewal and multi-potential 
differentiation, and can both initiate and maintain tumors. The prevailing names for these 
cells are “cancer stem cells (CSCs)” and “cancer initiating cells (CICs).” The CSC model 
implies a hierarchical organization within the tumor in which a limited number of CSCs 
represents the apex of the hierarchy. CSCs are chemo-resistant, radio-resistant, and 
quiescent, and have been shown to cause both metastasis and relapse. 
CSCs were first described in patients with acute myeloid leukemia (AML) by Dick et al. 
(Lapidot et al., 1994). As to be expected from leukemia stem cells, these CSCs exhibited the 
properties of self-renewal, proliferation and multipotency. The frequency of these leukemia-
initiating cells in the peripheral blood of those AML patients was one engraftment unit in 
250,000 cells. Dick et al. identified the leukemia-initiating cells as CD34+CD38-. 
 In the years since, CSCs have been identified in cancers of the breast(Al-Hajj et al., 2003), 
brain (Singh et al., 2003) and prostate, pancreas and lung (Eramo et al., 2008). In this chapter 
we review CSCs in lung cancer. 
2. Overview of CSCs in lung cancer 
2.1 Concept of CSCs 
Two major models have been described for tumor propagation: the clonal evolution model, 
which involves a stochastic component, and the CSC model, which is defined as 
hierarchical. According to the clonal evolution model, a neoplasm arises from a single cell of 
origin, whereupon an acquired genetic variability within the original clone allows a 
sequential selection to more aggressive clones, thereby allowing the tumor to progress. 
According to the CSC model, tumor cells are heterogeneous, and only the CSC subset has 
the ability to proliferate extensively and form new tumors (Wicha et al., 2006). Yet neither 
model alone can adequately explain the complex biology of tumor progression, resistance, 
and metastasis. Fig. 1 describes a new CSC hypothesis model that encompasses both the 
CSC hierarchical and clonal evolution components, a model in which pre-existing CSCs can 
transform into secondary CSCs (Takebe & Ivy, 2003). 
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Fig. 1. CSC development. 
A combination of DNA hits and niche microenvironmental factors can transform normal 
stem cells into primary CSCs or more differentiated cancer progenitor cells. Primary tumors 
are formed mostly from bulk tumor cells together with a small percentage of CSCs. The 
accumulation of additional DNA hits plus an altered niche microenvironment may drive 
primary CSCs to evolve into a genetically distinct population of secondary CSCs. Metastatic 
CSCs have the potential to proliferate and form metastatic tumors at distant sites composed 
mostly of bulk tumor cells together with a minority of metastatic CSCs (Takebe & Ivy, 2003). 
2.2 Origins of CSCs 
It remains uncertain whether CSCs originate from normal (somatic) stem cells that acquire 
oncogenic mutations or from non-stem cells of more differentiated forms that dedifferentiate 
and acquire stem-cell-like properties through mutation and reprogramming. CSCs can 
convert into differentiated cells, (Fig. 2) and evidence has suggested that these differentiated 
cells can acquire stem-cell-like properties via exogenous circumstances (including the niche), 
with plasticity. (Fig. 2) Cancer stem cells, for example, might be supplied from cancer cells 
of a non-metastatic epithelial form through a process referred to as “epithelial–
mesenchymal transition” (EMT). Besides tissue stem cells, bone marrow-derived cells 
(BMDCs) may also represent a potential source of malignancy (Fig. 2). Houghton et al. 
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showed that chronic infection of C57BL/6 mice with Helicobacter, a known carcinogen, 
repopulated the stomach with BMDCs (Houghton et al., 2004). Not long after, these cells 
progressed through metaplasia and dysplasia to intraepithelial cancer. These findings have 
broad implications for the multistep model of cancer progression, as they suggest that 
epithelial cancers can originate from bone-marrow-derived sources. The BMDCs may also 
be the precursors to CSCs in lung cancer. 
 
Fig. 2. Origins of CSCs 
2.3 How CSCs can be identified? 
Cancer stem cells are difficult to isolate in solid cancers, though several possible 
methodologies for attempting isolation are available. The process can be attempted with a 
surface marker (CD44 or CD133), or with non-adherent cells cultured in a specific condition 
(sphere-forming), or with side population (SP) cells identified by efflux of dye and an 
intracellular enzyme activity (aldehyde dehydrogenase, ALDH). As yet, there is no apparent 
consensus about the ‘best marker’ by which to identify CSCs. The gold standard assay in 
vivo, the assessment that isolates what most closely fits the definition of CSCs, may be serial 
transplantation in animal models. 
2.3.1 Surface marker 
CD44 or CD133 have served as CSC markers in many solid cancers. In a lung cancer study 
by Eramo et al., some tumors contained a rare population of CD133+ cancer stem-like cells 
that could both self-renew and generate an unlimited progeny of non-tumorigenic cells 
(Eramo et al., 2008). Eramo’s group found that the tumorigenic cells in small cell lung cancer 
(SCLC) and non-small cell lung cancer (NSCLC) consisted of rare populations of 
undifferentiated cells expressing CD133, an antigen present in the cell membrane of normal 
and cancer-primitive cells of the hematopoietic, neural, endothelial and epithelial lineages. 
In their cultures, lung cancer CD133+ cells were able to grow indefinitely as ‘tumor spheres.’ 
Meanwhile, Bertolini et al. independently reported similar findings using CD133+ cells 
isolated from 60 samples of human lung cancer (Bertolini et al., 2009). In their experiments, a 
CD133+ population was increased in primary NSCLC compared with normal lung tissue. 
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Importantly, the expression of CD133 in tumors was linked to shorter progression-free 
survival of NSCLC patients treated with platinum-based regimens. The proliferative 
potential, invasiveness, and chemoresistance of CD133+ cells isolated from human lung 
tumors are reported to depend on the expression of Oct-4 (Chen et al., 2008), a protein 
important in embryonic stem cell development. Lung cancer CD133+ cells have higher Oct-4 
expression, can self-renew, and robustly resist both chemotherapy agents and radiotherapy. 
Leung et al. found that stem cell-like properties are enriched in CD44+ subpopulations of 
some lung cancer cell lines, while most cancer cell lines showed no significant CD133 
expression (Leung et al., 2010). 
Urokinase plasminogen activator (uPA) and its receptor (uPAR/CD87) are major regulators 
of extracellular matrix degradation. Both take part in cell migration and invasion under 
physiological and pathological conditions. uPAR/CD87 was identified as one of the 
candidate CSC markers in SCLC (Gutova et al., 2007). uPAR+ cells exhibited multi-drug 
resistance, high clonogenic activity, and co-expression of the putative cancer stem cell 
markers CD44 and MDR1 in all of the SCLC cell lines examined. 
2.3.2 Sphere formation in culture 
Primary cancer cells can be propagated in spheroid cultures (Reynolds & Weiss, 1992 ), and 
doing so may allow extensive CSC characterization in vitro. The cells are grown in vitro as 
tumor spheres under nonadherent conditions using a serum-free medium supplemented 
with growth factors. Once cultured by this technique, they exhibit high clonogenic potential 
and readily renew themselves, generate differentiated progeny, and generate tumors in vivo 
(Singh et al., 2003; Ricci-Vitiani et al., 2007). From the major subtypes of lung cancer, ‘tumor 
spheres’ were found to possess CSC properties, both in vitro (expression of the CSC marker 
CD133, unlimited proliferative potential, extended abilities to self-renew and differentiate ) 
and in vivo (high tumorigenic potential, capacity to recapitulate tumor heterogeneity and 
mimic the histology of the specific tumor subtype from which CSCs were derived). Lung 
cancer ‘spheres’ are also extremely resistant to most conventional drugs currently used to 
treat lung cancer patients. This spheroid culture method serves adequately in isolating CSCs 
from clinical samples. 
2.3.3 Side population (SP) on flow cytometry 
SP cells are a subpopulation of cells rich in stem-cell-like characteristics. This subpopulation 
was first identified by flow-cytometer-based cell sorting defined by Hoechst 33342 dye 
exclusion (Goodell et al., 1996). Hoechst low cells are described as side population (SP) cells 
by virtue of their typical profiles in Hoechst red versus Hoechst blue bivariate fluorescent-
activated cell sorting dot plots. This test is based on ABCG2 transporter, the second member 
of the G subfamily of ATP binding cassette (ABC) transporters. ABCG2 is one of the most 
important multidrug-resistance transporters, and its substrates include Hoeschst 33342 
(Ding et al., 1996). SP cells were isolated from several solid cancers and certified to have 
stemness. Regarding the lung, SP cells isolated from six lung cancer cell lines exhibited 
higher invasiveness, higher resistance to chemotherapeutic drugs, and higher 
tumorigenicity in vivo compared with non-SP cells (Ho et al., 2007). Most of the SP fraction 
appeared to be in the G(0) quiescent state. Several SCLC cell lines examined by Salcido et al. 
contained a consistent SP fraction comprising <1% of the bulk population. SP cells had 
higher proliferative capacity in vitro, were able to efficiently self-renew, and exhibited 
www.intechopen.com
 
Cancer Stem Cells (CSCs) in Lung Cancer 
 
133 
reduced cell surface expression of differentiation markers. These cells also over-expressed 
many genes associated with cancer stem cells, drug resistance, and angiogenesis (Salcido et 
al., 2010). 
2.3.4 ALDH activity 
Aldehyde dehydrogenase (ALDH) is a detoxifying enzyme known for its role in the 
oxidation of intracellular aldehydes and for its contribution to the oxidation of retinol to 
retinoic acid in early stem cell differentiation (Jiang et al., 2009). Class 1 of the ALDH family 
(ALDH1) is the predominant ALDH isoform in mammals, and ALDH1 activity might serve 
as a common marker for both normal and malignant stem cell populations. Jiang et al. used 
the Aldefluor assay and fluorescence-activated cell sorting (FACS) analysis to isolate 
ALDH1-positive cells from human lung cancer cell lines. The ALDH1-positive cancer cells 
they isolated exhibited several of the important CSC properties: self-renewal, differentiation, 
multidrug resistance and expression of stem cell marker in vitro; tumor initiation and 
occurrence of a heterogeneous population of cancer cells in vivo. Jiang et al. also found that 
relatively high ALDH1 protein levels were positively associated with the stage and grade of 
the tumors, and inversely related to patient survival. 
2.3.5 Surface marker may vary even when the cells originate from the same tumor 
subtype 
The marked heterogeneity within CSC sub-populations underlines the need to find more 
specific single markers or to define new marker combinations for the prospective isolation 
of CSCs in solid tumors. CD133 is generally considered a stem cell marker, but CD133- 
tumors also contain cells with CSC activity. Independent studies have shown that CD133- 
glioblastoma cells can establish tumors in recipient mice with efficiencies comparable to 
those of CD133+ cells (Beier et al., 2007). In a study by Meng et al., CD133+ and CD133- 
subpopulations in lung cancer cells exhibited similar levels of colony formation, self-
renewal, proliferation, differentiation, and invasion, as well as similar resistance to 
chemotherapy drugs (Meng et al., 2009). As such, these CD133+ and CD133- subpopulations 
can be assumed to have contained similar numbers of cancer stem cells. In some cases, 
CD133 is undetectable among lung cancer samples. In a study by Tirino et al., for example, 
CD133+ was found in only 72% of 89 fresh specimens (Tirino et al., 2009). As to be expected 
from heterogeneous populations, the CSC phenotype is less than uniform, even when the 
cells originate from the same tumor subtype. Primary tumors with different genotypes at 
just one locus can have tumor-propagating cell populations with distinct markers. Fig. 3 
(Curtis et al., 2010) 
Transgenic mice carrying mutant Kras (left), mutant Kras with p53 deficiency (center), and 
mutant EGFR (right) all develop lung adenocarcinomas that harbor similar proportions of 
cells expressing the mouse stem cell marker Sca-1 (blue cells). The tumor-propagating 
capacity of Sca-1+ and Sca-1- cells from each primary tumor genotype was tested by 
implanting small numbers of sorted cells into the lungs of recipient mice. When isolated 
from primary Kras tumors, both Sca-1+ and Sca-1- cells generated secondary tumors that 
recapitulated the Sca-1 cell heterogeneity found in the primary tumor (left). Yet in tumors 
with the mutant Kras and p53 deficiency, Sca-1+ cells were better able to form secondary 
tumors (represented as larger tumors) than Sca-1- cells (center). Further, the secondary 
tumors derived from Sca-1+ cells harbored Sca-1+ cells in a proportion comparable to the  
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Fig. 3. Tumor Propagating Capacity of Sca-1+ Lung Cancer Cells 
primary tumor, whereas the few small tumors derived from Sca-1- cells had no detectable 
Sca-1+ population. These data suggest that the Sca-1+ cells in this tumor genotype are 
enriched in lung cancer stem cells. The opposite appears to be true in mutant EGFR 
adenocarcinomas, in which Sca-1- cells exhibited a greater capacity for generating secondary 
tumors (right). The distribution of Sca-1+ cells in secondary mutant EGFR tumors remains 
undetermined. Adapted with permission from Sullivan JP, Minna JD. Tumor oncogenotypes 
and lung cancer stem cell identity. Cell Stem Cell. 2010 Jul 2;7(1):2-4. 
2.4 Serial transplantation is the gold standard to validate CSCs 
Serial transplantation in animal models has been the gold standard to certify stemness, but 
animal models fail to mimic the human tumor microenvironment as closely as desired. This 
can be overcome, however, by orthotopic transplantation of candidate cancer-initiating cells 
back into their normal microenvironment. When working with putative lung cancer-
initiating cells, this can be achieved by intratracheal delivery into the lung cavity using a 
methodology employed for the delivery of an adeno-Cre virus in sporadic murine models of 
human lung cancer (Meuwissen et al., 2001, 2003). In serial transplantation in animal 
models, the presence of residual immune effector cells in recipient mice may influence the 
efficiency of human cell engraftment in NOD/SCID mice. Shultz et al. showed that NOD-
scid IL2Rγnull (NSG) mice engrafted with human hemopoietic stem cells generate a 6-fold 
higher percentage of human CD45+ cells in host bone marrow compared to similarly treated 
NOD-scid mice (Shultz et al., 2005). 
2.5 How do we overcome obstacles of researching CSCs? 
It would be impossible to extensively investigate CSCs without expanding the cell 
populations in vitro. Given the low frequency of lung CSCs within primary tumor tissues, 
we have difficulty in finding agents which can kill CSCs with strong selective toxicity. There 
are two methods to surmount this obstacle.  
2.5.1 Sphere formation is the best way to obtain CSCs from patients 
This experimental strategy is the best approach so far developed to obtain the unlimited 
expansion of a tumorigenic lung cancer cell population from primary patients. As such, it 
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serves as a powerful enabler for extensive studies on these cells. Yet CSC spheres are 
difficult to establish from epithelial tumors, particularly in the case of lung cancer. Indeed, 
only a few specialized laboratories in the world are able to use CSC spheroids from primary 
tumors. And as another potential limiting factor, CSCs constitute 5 - 30% of the cells in an 
average tumor sphere (Eramo et al., 2008). 
2.5.2 Inducing CSCs by EMT 
Another potential solution is the generation of ‘induced’ CSCs (iCSC). The induction of an 
epithelial-mesenchymal transition (EMT) in normal or neoplastic mammary epithelial cell 
populations has been shown to enrich the cells with stem-like properties. Gupta et al. 
demonstrated that normal and cancer cell populations experimentally induced into an EMT 
also exhibited an increased resistance to chemotherapy drug treatment. When cancer cell 
populations are induced to pass through an EMT, the proportion of CSCs could increase 
(Gupta et al., 2009). 
2.6 Lung stem cells and lung cancer stem cells  
The lung is a complex organ made up of regionally and functionally distinct cell 
phenotypes. A diverse class of lung stem cells drives the development and turnover of these 
populations. The epithelium of the adult airways consists of three distinct compartments 
arranged along a proximal-distal axis. One factor impeding efforts to demonstrate the 
existence of adult lung stem cells has been the slow turnover rates in the adult epithelium. 
Yet in spite of this factor, findings from new studies on pollutant- and pathogen-induced 
injuries leading to massive lung cell proliferation suggest that adult stem cells are present in 
each of the epithelial compartments. These different tumor subclasses may arise from distinct 
cells of origin localized within a defined regional compartment/microenvironment. (Fig. 4) 
 
 
Fig. 4. Airway stem cell microenvironments and associated human carcinomas. 
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A schematic diagram of the mouse lung highlighting the spatially distinct cellular 
environments shown to harbour airway stem/progenitor cells. Candidate epithelial niches 
(depicted on the right hand side) have been identified and found to exist in spatially defined 
regions: the tracheal submucosal gland ducts, neuroendocrine bodies (NEB) of the 
bronchi/bronchioles, and the broncholalveolar duct junction (BADJ). Adapted with 
permission from Sutherland KD, Berns A. Cell of origin of lung cancer. Mol Oncol. 2010 
Oct;4(5):398. 
2.6.1 Adenocarcinoma 
The distal airways are composed of respiratory bronchioles and alveoli lined with cuboidal 
epithelium. The bronchioalveolar duct junction (BADJ) has been identified as a 
microenvironment harboring airway stem cells (Giangreco et al., 2002). With regard to 
tumorigenicity, Jackson et al. reported that lung tumors were suggested to initiate by oncogenic 
K-Ras activation appeared to be derived from targeted cells located in the BAD (Fig. 5A) 
(Jackson et al., 2001). Kim et al. have isolated bronchioalveolar stem cells (BASCs), a regional 
pulmonary stem cell population, in BADJ, and have identified the candidate origins of CSCs in 
lung adenocarcinomas (Kim et al., 2005). The BASCs in their experiments resisted bronchiolar 
and alveolar damage and proliferated during epithelial cell renewal in vivo. The BASCs also 
exhibited self-renewal capability and multipotent properties in clonal assays, and expanded in 
response to oncogenic K-ras in culture and developed to the lung tumor precursors in vivo. 
2.6.2 Squamaous carcinoma 
The histopathology and gene expression patterns of mouse lung SCC-like lesions frequently 
resemble those of tracheal basal cell progenitors. This presents the appealing prospect that 
these are the target cells of origin in this subclass of lung cancer (Fig. 5C). Keratin (K) 5/14-
expressing basal cells are located at the submucosal gland duct junctions or 
intracartilaginous boundaries and are capable of self-renewal, proliferation, and 
multipotency (Borthwick et al., 2001; Hong et al., 2004a, 2004b; Rawlins et al., 2008; Rock et 
al., 2009). As such, K 5/14-expressing cells are the putative major airway stem cells. But the 
clear relationship between basal progenitors and lung SCC has not been established yet. 
2.6.3 Small cell carcinoma 
The specific cell population that gives rise, upon genetic alteration, to SCLC remains to be 
identified. Human and mouse SCLC predominately localize to the midlevel bronchioles and 
typically express a range of neuroendocrine markers, including calcitonin-gene related 
peptide (CGRP) and other neuropeptides normally expressed within pulmonary 
neuroendocrine cells (PNECs) (Meuwissen et al., 2003). Some investigators have 
hypothesized, based on these observations, that a rare population of PNECs are the 
progenitors of SCLC. (Fig. 5B) In the mouse lung, microenvironments found in close 
proximity to  neuroepithelial bodies (NEB) have been shown to maintain putative stem cell 
populations containing both PNECs and variant CCSP-expressing (vCE) cells (Reynolds et 
al., 2000a). These may be the CSCs of small cell carcinoma. 
2.6.4 Human lung stem cells 
Kajstura et al. recently identified a set of potential stem cells in the human lung (Kajstura et 
al., 2011). These cells were self renewing, clonogenic and multipotent in vitro. And when  
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Fig. 5. Schematic overview of the putative role of normal tissue stem/progenitor cells in 
lung cancer. 
(A) BADJ contains a rare cell population that expresses both Clara-specific and alveolar-
specific markers. These cells are BASCs. K-Ras activation enhances the proliferation of 
BASCs. (B) Two hypotheses on the origin of lung NE tumors. NEBs in the epithelial lining of 
the bronchi harbor PNECs associated with vCEs. The first hypothesis proposes that (i) NE 
tumors arise from these PNECs. The second hypothesis proposes (ii) that NE hyperplasia 
and SCLC arise from a less-differentiated progenitor-like cell (for example vCE). (C) Given 
the basal-like phenotype of SCC, one could hypothesize that squamous cell tumors arise 
from these basal stem cells. Adapted with permission from Sutherland KD, Berns A. Cell of 
origin of lung cancer. Mol Oncol. 2010 Oct;4(5):397-403. 
injected into a mouse model of lung injury, they regenerated bronchioles, alveoli, smooth 
muscle, pulmonary vessels and many other lung components. The experiments were 
performed using c-kit as a stem cell marker. These results are exciting, though rigorous 
validation will be required. CSCs of the human lung with the potential to differentiate into 
NSCLCs and SCLCs may originate from not only regional lung stem cells, but also 
multipotent stem cells. 
2.6.5 Analysis of important molecules and pathways of CSCs in the mouse model 








Bmi1 is requisite for K-ras–induced tumorigenesis in the mouse model (Dovey et al., 2008). 
Loss of Bmi1 in K-ras transgenic mice decreased the prevalence and progression of lung 
tumors and impaired BADJ stem cell proliferation and self-renewal in vivo and in vitro. 
2.6.5.2 PI3K/PTEN/Akt 
The phosphoinositide 3-kinases (PI3K)/phosphatase and tensin homolog (PTEN)/protein 
kinase B (Akt) pathway is requisite for normal stem cell function. The tumor suppressor 
PTEN encodes a lipid phosphatase that negatively regulates the PI3K /Akt cell survival 
pathway. In NSCLC, loss of PTEN protein expression occurs frequently (Marsit et al., 2005). 
 
 
Fig. 6. Loss of PTEN function results in accumulation of PIP3, which activates a cascade of 
signaling molecules. 
AKT activation inhibits pro-apoptotic factors and stimulates cell cycle progression. The loss 
of PTEN function leads to increased cell survival and proliferation. RTK, receptor tyrosine 
kinase. Adapted with permission from Hill R, Wu H. PTEN, stem cells, and cancer stem 
cells. J Biol Chem. 2009 May 1;284(18):11755-9. 
Recent work has linked the PI3K/PTEN/Akt pathway to lung cancer stem cells and to the 
suppression of K-ras mutations. (Fig. 6) Spontaneous lung adenocarcinomas develop in 
transgenic mice with an inducible loss of PTEN expression in bronchioalveolar cells (Yanagi 
et al., 2007). Interestingly, a loss of PTEN expression resulted in K-ras mutations in 33% of 
mice and developed spontaneous adenocarcinomas. A loss of PTEN expression and PI3K 
activation may elicit increases in BADJ stem cells, side-population (SP) cells, and the 
frequency of K-ras mutations, and thereby initiate the development of lung adenocarcinoma 
over time. 
2.6.5.3 Hedgehog 
The Hedgehog (Hh) signaling pathway acts as an important regulator of stem cell fates 
during embryonic development and has been linked to SCLC (Watkins et al., 2003a, 2003b). 
The observation that intraepithelial Hh signaling is increased after naphthalene-induced 
airway injury suggests that progenitor cells activate Hh signaling in response to injury. 
Increased Hh signaling is also observed in the lungs of PTEN-deficient mice that develop 
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spontaneous lung adenocarcinomas in conjunction with BADJ stem cell expansion, and thus 
may play a causal role in this process (Yanagi et al., 2007). 
2.6.5.4 Wnt 
The Wnt developmental pathway is an another critical regulator of embryonic lung stem 
cells (Reynolds et al., 2008; Zhang et al., 2008). In adult mice, conditional deletion of p38+, a 
known downstream target of noncanonical Wnt signaling (Ma & Wang, 2007), leads to an 
expansion of CCSP+SP-C+ stem cells, hyperproliferation, and increased sensitization to K-
ras–induced tumorigenesis (Ventura et al., 2007). 
2.7 Therapeutic strategy against CSCs 
CSCs are thought to be responsible for disease relapse or metastasis, and also for resistance 
to radiation or conventional chemotherapy. CSCs showed increased quiescence in vivo and 
in vitro, which suggests that they may respond poorly to conventional treatments designed 
to mainly kill the proliferating cells or terminally differentiated cells forming the bulk of 
tumors (Guan et al., 2003). Several therapies against CSCs have been considered, but none 
have been fully developed for lung cancer CSCs. The remainder of this chapter will discuss 
strategies for targeting CSCs in various organs. 
2.7.1 Targeting the key molecule (stem cell marker), key gene & key signaling 
pathways 
Given that CSCs share many of the same features as normal stem cells, there is a potential 
risk of killing normal stem cells while targeting CSCs. It thus becomes important to further 
characterize the similarities and differences between these two types of stem cells. New 
therapeutic approaches to selectively target CSC-specific markers, genes, and pathways are 
needed. 
2.7.1.1 Antibody-based treatment against surface markers 
One recently introduced therapeutic approach for human AML employs an activating mAb 
directed to the adhesion molecule CD44, a known CSC marker of AML (Jin et al., 2006). The 
in vivo administration of this Ab to NOD/SCID mice transplanted with human AML 
markedly reduced leukemic repopulation. Mechanistically, CD44-specific Ab treatment 
induced differentiation to a more mature cancer cell progeny that were unable to establish 
robust leukemia upon xenotransplantation. For solid tumors, CD13, a CSC marker of 
hepatocellular carcinoma, is expected to become a target of CSC therapy (Haraguchi et al., 
2010). 
2.7.1.2 Inhibition of essential pathways in the CSCs function 
The eventual goal is to generate targeted therapeutics that inhibit essential pathways in the 
CSC fraction. It will probably be complicated to target these pathways, as the same 
pathways are also pivotal in normal stem cell function. The Wnt pathway, hedgehog 
pathway, and notch pathway are all reportedly essential for maintaining stemness. The 
blocking of these pathways thus holds promise as a therapeutic approach. Many reports and 
target drugs have been published and developed in pursuit of such a therapy, but only few 
of these reports have touched upon lung cancer CSCs. The hedgehog pathway may play an 
important role in lung CSCs, as the pharmacological inhibition of this pathway reduced the 
growth of lung tumor cells in xenograft models (Watkins et al., 2003a). Suppression of the 
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Notch pathway by treatment with either a -secretase inhibitor or stable expression of 
shRNA against NOTCH3 significantly decreased ALDH+ lung cancer cells, and 
commensurate reductions in tumor cell proliferation and clonogenicity were observed 
(Sullivan et al., 2010). Notch signaling thus appears to take part in lung cancer stem cell 
maintenance. 
2.7.1.3 Blocking of the stemness gene 
CD133+ cells in lung cancer exhibit higher Oct-4 expression. Oct-4 plays a crucial role in 
maintaining the self-renewing, cancer stem-like, and chemoradioresistant properties of 
CD133+ cells. Knock-down of Oct-4 expression can significantly inhibit the abilities of tumor 
invasion and colony formation, increase apoptotic activities, and enhance the treatment 
effect of chemoradiotherapy (Chen et al., 2008). The downregulation of transcription factor 
SOX in lung CSCs reportedly suppresses growth and metastasis (Xiang et al., 2011), and the 
blocking of the SCF/c-kit signaling pathway inhibits CSC proliferation and survival after 
chemotherapy exposure in human lung cancer cell lines (Levina et al., 2010). Cisplatin 
treatment eliminated most of the tumor cells, but unlike the blocking of c-kit, it was 
unsuccessful in eliminating CSCs. A combination treatment with cisplatin and c-kit blocking 
prevented the growth of both tumor cell subpopulations. 
2.7.2 Regulation of micro RNA 
Micro RNAs can affect the signaling pathways that influence stem cell self-renewal. A lack 
of let-7 is required for self renewal in vitro and for tumorigenicity in vivo. In other words, an 
overexpression of let-7a reduces self renewal and proliferative capacity and converts highly 
malignant and metastasizing CSCs into less malignant cells (Yu et al., 2007). 
2.7.3 Induction of diffentiation of CSCs 
Differentiation therapy aims at converting tumorigenic CSCs in their non-tumorigenic 
progeny. Treatment with bone morphogenic protein 4 (BMP4) reduced the tumor-initiating 
cell pool in a glioma model and markedly slowed down tumor growth in vivo without toxic 
side effects (Piccirillo et al., 2006). 
2.7.4 Altering the CSCs’ environment (niche) 
The stem cell niche plays an important role in maintaining CSCs and apparently enhances 
the therapy resistance of CSCs by sheltering the cells from diverse insults (Folkins et al., 
2007). Perivascular, hypoxic, premetastatic and stromal myofibroblast niches have all been 
reported. The perivascular niche in brain tumors has been shown to contribute directly to 
the generation of CSCs and tumor growth. Anti-angiogenic therapy using vascular 
endothelial growth factor inhibitors not only depleted tumor vascularization, but also 
ablated CSCs in the xenograft (Calabrese et al., 2007). While some stem cells are 
perivascular, others may occupy hypoxic niches and be regulated by O2 gradients (Parmar 
et al., 2007). However, the underlying mechanisms are still unclear. O2 availability may have 
a direct role in stem cell regulation through the HIF-1 modulation of Wnt/-catenin 
signaling (Mazumdar et al., 2010). These niches are expected to become targets of CSC 
therapy. In experiments with colon adenocarcinomas, Vermeulen et al. found that 
hepatocyte growth factor and other myofibroblast-secreted factors activate CSC 
clonogenicity (Vermeulen et al., 2010). More significantly, myofibroblast-secreted factors 
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restored the CSC phenotype in more differentiated tumor cells both in vitro and in vivo. 
Vermeulen’s group therefore propose that the stemness of colon cancer cells is in part 
orchestrated by the microenvironment. 
2.7.5 Activation of reactive oxygen species (ROS) 
CSCs have the ability to keep ROS levels low. Subsets of CSCs in some tumors contain lower 
ROS levels and enhanced ROS defenses compared to their non-tumorigenic progeny. This 
may contribute to tumor radioresistance. Overcoming low ROS levels within CSCs may be a 
useful method for improving local and systemic oncologic therapies (Diehn et al., 2009). 
Haraguchi et al. found that CD13 is a marker for semiquiescent CSCs in human liver cancer 
cell lines and clinical samples. Mechanistically, CD13 reduced ROS-induced DNA damage 
after genotoxic chemo/radiation stress and protected cells from apoptosis. In mouse 
xenograft models, a combination of a CD13 inhibitor and the genotoxic chemotherapeutic 
fluorouracil (5-FU) drastically reduced tumor volume compared with either agent alone. 
Thus, the combination of a CD13 inhibitor with a ROS-inducing chemo/radiation therapy 
may improve the treatment of liver cancer (Haraguchi et al., 2010). CD44 is an adhesion 
molecule expressed in cancer stem-like cells in gastric cancer. Ishimoto et al. showed that a 
CD44 variant (CD44v) interacts with xCT, a glutamate-cystine transporter, and controls the 
intracellular level of reduced glutathione (GSH) (Ishimoto et al., 2011). Human 
gastrointestinal cancer cells with strong CD44 expression showed an enhanced capacity for 
GSH synthesis and defense against ROS. Ablation of CD44 induced a loss of xCT from the 
cell surface and suppressed tumor growth in a transgenic mouse model of gastric cancer. 
The activation of ROS may be viable as another target therapy for CSCs. 
2.7.6 Overcoming of chemoresistance and radioresistance in CSCs 
Reversing chemoresistance in CSC populations can be achieved through a specific blockade 
of multidrug resistance ABC transporters (Frank et al., 2005). Enhanced drug efflux 
mediated by ABCB1 P-glycoprotein and related ATP-binding cassette transporters is one of 
several mechanisms of multidrug resistance thought to impair chemotherapeutic success in 
human cancers. In CD133+ CSC in malignant melanoma, ABCB5, a novel human ABC 
transporter, mediates melanoma resistance to the chemotherapeutic agent doxorubicin, and 
this effect is reversible by both mAb-mediated inhibition of ABCB5-dependent drug efflux. 
In addition, ABCB5 gene silencing substantially increases the sensitivity of human 
melanoma cells to the anticancer chemotherapeutics 5-fluorouracil (5-FU) and camptothecin 
(Huang et al., 2004). CSC-targeted therapeutic approaches might also include strategies 
directed at reversal of radioresistance. Bao et al. reported that CD133+ human glioma CSCs 
contributed to tumor radioresistance by preferentially activating the DNA damage 
checkpoint response and enhancing the DNA repair capacity (Bao et al., 2006). An inhibition 
of the Chk1 and Chk2 checkpoint kinases reversed the radioresistance of CD133+ glioma 
CSCs in their experiments. 
2.7.7 Supressing EMT and inducing MET 
EMT in carcinoma seems to be associated with the acquisition of a CSC phenotype endowed 
with a more invasive and metastatic phenotype. As such, a new drug to suppress EMT is 
expected as a target therapy for CSCs. Metastatic progression might involve the 
dissemination of CSCs at tumor margins that have undergone EMT. Thus, the 
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mesenchymal-epithelial transition (MET) seems to hold promise as a therapy. Gupta et al. 
identified small molecules (salinomycin) that specifically inhibit cancer stem cell 
proliferation through the induction of MET (Gupta et al., 2009). 
3. Conclusion 
Though targeted therapies have been developed, we have witnessed only limited 
improvement in the prognosis of lung cancer patients. Ultimately, patient cure will require 
the eradication of all cells within a cancer. From this standpoint, combination therapies 
targeting both CSCs and bulk cancer populations hold promise. In the coming years we 
must clarify the origin of CSCs, find more specific CSC markers, elucidate the CSC niche, 
and develop more effective innovative agents against resistant tumorigenic lung CSCs. 
CSCs may vary in different lung cancers, so personalized CSC therapy may be needed. 
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